Media Summary: PHUSE Spring House Virtual Single Day Event Qi Liu, PhD, MStat, FCP, Associate Director for Innovation and Partnership for the Office of Have a question for our presenters or panelists? Please email OTPEvents@

Fda S Clinical Regulatory Perspective - Detailed Analysis & Overview

PHUSE Spring House Virtual Single Day Event Qi Liu, PhD, MStat, FCP, Associate Director for Innovation and Partnership for the Office of Have a question for our presenters or panelists? Please email OTPEvents@ Advancing the Science of Patient Input in the John Leighton, PhD, director, Division of Hematology, Oncology, Toxicology, Office of Oncologic Diseases (OOD), CDER, ...

Photo Gallery

FDA’s Clinical Regulatory Perspective: Designing First-In-Human Trial for Cellular and Gene Therapy
FDA RWE Regulatory Perspective
CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products
On the RISE: Controls in Rare Disease Clinical Trials for Small and Diminishing Populations
CDER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products
Clinical Pharmacology Regulatory Sciences in Drug Development and Precision Medicine
CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products
Advancing Pediatric CGT Clinical Trials: Scientific, Ethical, Regulatory & Practical Considerations
CBER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products
CDER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products
A Perspective Review of FDA's Draft Guidance on the Use of Bayesian Methodology in Clinical Trials
FDA Lecture: Advancing the Science of Patient Input in the Regulatory Settings
Sponsored
Sponsored
View Detailed Profile
FDA’s Clinical Regulatory Perspective: Designing First-In-Human Trial for Cellular and Gene Therapy

FDA’s Clinical Regulatory Perspective: Designing First-In-Human Trial for Cellular and Gene Therapy

FDA

FDA RWE Regulatory Perspective

FDA RWE Regulatory Perspective

PHUSE Spring House Virtual Single Day Event

Sponsored
CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

Learn directly from the

On the RISE: Controls in Rare Disease Clinical Trials for Small and Diminishing Populations

On the RISE: Controls in Rare Disease Clinical Trials for Small and Diminishing Populations

Conducting

CDER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

CDER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

Learn directly from the

Sponsored
Clinical Pharmacology Regulatory Sciences in Drug Development and Precision Medicine

Clinical Pharmacology Regulatory Sciences in Drug Development and Precision Medicine

Qi Liu, PhD, MStat, FCP, Associate Director for Innovation and Partnership for the Office of

CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

Learn directly from the

Advancing Pediatric CGT Clinical Trials: Scientific, Ethical, Regulatory & Practical Considerations

Advancing Pediatric CGT Clinical Trials: Scientific, Ethical, Regulatory & Practical Considerations

Have a question for our presenters or panelists? Please email OTPEvents@

CBER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

CBER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

Learn directly from the

CDER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

CDER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

Learn directly from the

A Perspective Review of FDA's Draft Guidance on the Use of Bayesian Methodology in Clinical Trials

A Perspective Review of FDA's Draft Guidance on the Use of Bayesian Methodology in Clinical Trials

Presentation Title: A

FDA Lecture: Advancing the Science of Patient Input in the Regulatory Settings

FDA Lecture: Advancing the Science of Patient Input in the Regulatory Settings

Advancing the Science of Patient Input in the

FDA Oncology Drug Development Overview – Past to Present

FDA Oncology Drug Development Overview – Past to Present

John Leighton, PhD, director, Division of Hematology, Oncology, Toxicology, Office of Oncologic Diseases (OOD), CDER, ...